CJC-1295 + Ipamorelin Stack
The most-researched growth-hormone secretagogue pairing — a GHRH analog combined with a selective GHRP.
Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Why these two are stacked
CJC-1295 (a long-acting GHRH analog) increases the amplitude of natural GH pulses, while ipamorelin (a selective ghrelin-receptor / GHRP agonist) increases the frequency of those pulses. Combined GHRH + GHRP administration shows a supra-additive serum GH rise vs either agent alone, without raising cortisol or prolactin the way older GHRPs (GHRP-2, GHRP-6) do.
GHRH analogs and ghrelin-receptor agonists act on two different pathways at the pituitary somatotroph. Combining them recruits a larger pool of GH from storage vesicles while preserving the natural pulsatile pattern that downstream IGF-1 signaling depends on. Ipamorelin's selectivity is what makes the pair attractive — it avoids appetite, prolactin, and cortisol effects of less-selective GHRPs.
Researched together for
- •Synergistic GH release vs either peptide alone
- •Preservation of natural pulsatile GH pattern
- •Sleep-onset GH amplitude (PM dosing)
- •Post-exercise recovery and lean-mass research
- •No significant cortisol or prolactin elevation
Sample weekly schedule
| When | Research protocol |
|---|---|
| Mon–Fri · evening | Subcutaneous dose 60–90 minutes before bed on an empty stomach. |
| Sat–Sun · off | Two off-days are common in research to limit receptor desensitization. |
| Cycle length | Typical research cycles run 8–12 weeks followed by a 4-week washout. |
Timing notes
- •Evening dosing aligns with the natural nocturnal GH pulse and avoids blunting from postprandial insulin/glucose.
- •Empty-stomach window of ~2 hours before and ~30 minutes after is standard.
- •Some protocols add a pre-workout dose on training days, still separated from carbs/fat.
Female vs male research notes
Endogenous GH pulses are naturally higher in pre-menopausal women; research often uses lower doses and emphasizes PM-only.
Men show lower baseline GH pulse amplitude past age 30; the full 5-on / 2-off schedule is more common.
Stack-specific considerations
- •Not FDA-approved for general use; both peptides are research-grade.
- •Water retention, transient flushing, and vivid dreams are commonly noted.
- •IGF-1 should be monitored — chronic supra-physiologic IGF-1 has theoretical safety concerns.
- •Avoid in pregnancy, breastfeeding, active malignancy, or diabetic retinopathy.
Frequently asked
Q.Why is CJC-1295 + ipamorelin the gold-standard GH stack?
It combines a GHRH analog with a selective GHRP — the two pathways are additive at the pituitary, and ipamorelin's selectivity avoids cortisol and prolactin spikes seen with older GHRPs.
Q.Should CJC-1295 be with or without DAC?
Without-DAC (Mod GRF 1-29) preserves the natural pulsatile GH pattern and is what most published research uses with ipamorelin. With-DAC produces a sustained 'GH bleed' that diverges from physiological pulsatility.
Q.How long until research subjects see changes?
Sleep and recovery changes often appear in 1–2 weeks; body-composition shifts typically take 6–8 weeks of consistent dosing.
Q.Can the two peptides be drawn into the same syringe?
Yes — they are chemically compatible and most protocols co-administer them in a single SC injection.
Q.Does the stack raise IGF-1 indefinitely?
No. IGF-1 rises during the cycle and returns toward baseline within weeks of stopping. This is why on/off cycling is the norm.
Q.Will this stack help with fat loss?
GH itself is lipolytic and research shows modest fat-loss effects, but the combination is researched primarily for recovery, sleep, and lean-mass preservation.
Q.Is it safe to combine with a GLP-1 (semaglutide / tirzepatide / retatrutide)?
Some clinics study the combination for body-recomposition during weight loss, but published evidence is sparse. Coadministration is not FDA-approved and should only be considered under physician supervision.